Polomar Health Services Inc.
Pharmaceutical preparations company · NV · FY ends Dec · Revenue $3M · -295.04% margin
$0.13
+$0.00 (+0.00%)
Price from 3 days ago
The business is unprofitable at the operating level (-1627.55% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1002.0% YoY with margins expanding 581.6pp.
ROIC dropped from -23.52% to -192.42%, capital efficiency is deteriorating.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3M
▲ +1002.0% YoY
Net Income (TTM)
-$9M
▼ -697.8% YoY
Op. Margin
-295.04%
▲ +581.6pp YoY
ROIC
-378.66%
▼ -168.9pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$7K
▲ +61.2% YoY
Net Debt
-$179K
Net Cash Position
Cash & Equiv.
$179K
3Y CAGR: +165.8%
Continue Research
SourceComputed from the 10-Q filed 10 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Price from market data, last close as of 15 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Polomar Health Services (PMHS) overvalued?
Polomar Health Services (PMHS)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Polomar Health Services scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Polomar Health Services a high-quality business?+
Polomar Health Services scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -295.0% operating margin and a -378.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Polomar Health Services a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh PMHS's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.